283 related articles for article (PubMed ID: 11693459)
1. Interferon-beta therapy in multiple sclerosis: evidence for a clinically relevant dose response.
Goodin DS
Drugs; 2001; 61(12):1693-703. PubMed ID: 11693459
[TBL] [Abstract][Full Text] [Related]
2. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
3. Early treatment and dose optimisation BENEFIT and BEYOND.
Hartung HP
J Neurol; 2005 Sep; 252 Suppl 3():iii44-iii50. PubMed ID: 16170501
[TBL] [Abstract][Full Text] [Related]
4. The importance of maintaining effective therapy in multiple sclerosis.
Durelli L; Clerico M
J Neurol; 2005 Sep; 252 Suppl 3():iii38-iii43. PubMed ID: 16170500
[TBL] [Abstract][Full Text] [Related]
5. Long-term benefits of early and high doses of interferon beta-1a treatment in relapsing-remitting multiple sclerosis.
Chofflon M; Ben-Amor AF
Clin Neurol Neurosurg; 2002 Jul; 104(3):244-8. PubMed ID: 12127662
[No Abstract] [Full Text] [Related]
6. History of modern multiple sclerosis therapy.
Lublin F
J Neurol; 2005 Sep; 252 Suppl 3():iii3-iii9. PubMed ID: 16170498
[TBL] [Abstract][Full Text] [Related]
7. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab.
Barbero P; Bergui M; Versino E; Ricci A; Zhong JJ; Ferrero B; Clerico M; Pipieri A; Verdun E; Giordano L; Durelli L;
Mult Scler; 2006 Feb; 12(1):72-6. PubMed ID: 16459722
[TBL] [Abstract][Full Text] [Related]
8. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
9. The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS.
O'Connor P;
Clin Ther; 2003 Nov; 25(11):2865-74. PubMed ID: 14693310
[TBL] [Abstract][Full Text] [Related]
10. Interferon beta treatment in relapsing-remitting multiple sclerosis. A review.
Grigoriadis N
Clin Neurol Neurosurg; 2002 Jul; 104(3):251-8. PubMed ID: 12127664
[No Abstract] [Full Text] [Related]
11. Interferon beta-1a in relapsing-remitting multiple sclerosis.
Blumhardt L
Hosp Med; 1999 Mar; 60(3):192-5. PubMed ID: 10476242
[TBL] [Abstract][Full Text] [Related]
12. Interferon beta 1a.
Pozzilli C; Koudriavtseva T
Baillieres Clin Neurol; 1997 Oct; 6(3):481-93. PubMed ID: 10101585
[TBL] [Abstract][Full Text] [Related]
13. An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis.
Vollmer TL; Phillips JT; Goodman AD; Agius MA; Libonati MA; Giacchino JL; Grundy JS
Mult Scler; 2004 Oct; 10(5):511-20. PubMed ID: 15471366
[TBL] [Abstract][Full Text] [Related]
14. High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis.
Hartung HP
Expert Opin Pharmacother; 2009 Feb; 10(2):291-309. PubMed ID: 19236200
[TBL] [Abstract][Full Text] [Related]
15. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
[TBL] [Abstract][Full Text] [Related]
16. Relationship between disease activity and dose-response relationships with beta interferon therapies in the treatment of multiple sclerosis.
Jeffery DR
J Neurol Sci; 2000 Sep; 178(1):2-9. PubMed ID: 11018242
[TBL] [Abstract][Full Text] [Related]
17. Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.
Arnason BG
J Neurol; 2005 Sep; 252 Suppl 3():iii28-iii33. PubMed ID: 16170497
[TBL] [Abstract][Full Text] [Related]
18. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.
Río J; Tintoré M; Nos C; Téllez N; Galán I; Montalban X
J Neurol; 2005 Jul; 252(7):795-800. PubMed ID: 15772741
[TBL] [Abstract][Full Text] [Related]
19. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis.
Richert ND; Ostuni JL; Bash CN; Leist TP; McFarland HF; Frank JA
Mult Scler; 2001 Feb; 7(1):49-58. PubMed ID: 11321194
[TBL] [Abstract][Full Text] [Related]
20. Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study.
Clanet M; Kappos L; Hartung HP; Hohlfeld R;
Mult Scler; 2004 Apr; 10(2):139-44. PubMed ID: 15124757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
